ArticlePreventive medicine reports2022
Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands.
Article in Preventive medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Economic evaluation of 22 HPV vaccination strategies to minimize the risk of penile, anal, and oropharyngeal cancers in Chinese males: A Markov model analysis.Human vaccines & immunotherapeutics · 2026Article
- The Attitude-Uptake Gap in HPV Vaccination Among Adults Aged 18-45 Years in Poland: Sociodemographic and Psychosocial Correlates.Vaccines · 2026Article
- HPV Vaccine: An Effective but Underutilized Prevention Tool.International journal of environmental research and public health · 2025Article
- Inequalities in HPV vaccine offer among Italian regions: Analysis of regional prevention plans.Human vaccines & immunotherapeutics · 2025Article
- A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy.Human vaccines & immunotherapeutics · 2025Article
- Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study.BMC public health · 2025Article
- Acceptance of human papillomavirus vaccine among boys in Asia: A narrative review.Human vaccines & immunotherapeutics · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the Netherlands, the Health Council has advised that the human papillomavirus (HPV) vaccination should be offered to both boys and girls. Additionally, boys and men up to the age of 26 years should be included in a catch-up program. In this study, we examine the cost-effectiveness of this HPV catch-up program. We used a static Markov model to estimate the amount of cancers prevented and the incremental cost-effectiveness ratio (ICER) for different scenarios. Vaccinating men from 12 until the age of 26 years would result in an average of 48 cancer cases prevented in every cohort (an estimated total of 720 cases), with an average ICER of €32,256. We found that the catch-up vaccination program results in a relevant number prevented cases against an acceptable cost-effectiveness ratio. Policymakers should take these findings into account when evaluating a gender-neutral HPV vaccination program in the Netherlands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.